Anglo-Swedish drug major AstraZeneca has appointed Sean Bohen as executive vice president of global medicines development and chief medical officer. 24 August 2015
Germany’s Merck KGaA named Isabel De Paoli head of group communications effective March 9, 2016. She will succeed Walter Huber, who is set to retire in March next year. 30 July 2015
Pharma giant Merck & Co on Tuesday said it has agreed to buy Israel-based drugmaker cCAM Biotherapeutics for as much as $605 million in a bid to expand its immuno-oncology portfolio. 29 July 2015
US biotech major Gilead Sciences on Tuesday named William Lee the executive vice president (EVP) for research, and Brett Pletcher the EVP and general counsel. Both Mr Lee and Mr Pletcher will join the company’s senior leadership committee. 28 July 2015
Privately-held pharma company Otic, focused on ear, nose and throat disorders, has appointed Gregory Flesher as chief executive and member of the board. 27 July 2015
Synthetic biology specialist Intrexon Corp has appointed Jack Bobo as senior vice president, chief communications officer, Samuel Broder as senior vice president, head of health, and Joel Liffman as senior vice president, finance. 22 July 2015
US biotech major Biogen announced on Friday that head of R&D Douglas Williams will leave the company at the end of July to become chief executive of an as-yet unnamed start-up biotechnology company. 11 July 2015
Waypoint Capital, the business enterprise for investments associated with the Bertarelli family, has named Christopher Viehbacher as the managing partner of its US-based Gurnet Point Capital (GPC) fund. 24 June 2015
American pharma company Pozen has appointed Mark Glickman as chief commercial officer, Eric Trachtenberg as deputy general counsel, and Jennifer Armstrong as executive vice president of human resources and administration. 22 June 2015
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
French cancer focused biotech Transgene has appointed two seasoned leaders in oncology who will be instrumental in advancing the company’s innovative immunotherapy programs 10 September 2024
Italy-based biotech AAVantgarde Bio has appointed Jayashree Sahni as its new chief medical officer, replacing Naveed Shams, who has held the role since 2022. 10 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
Biosimilar-focused biopharmaceutical company and contract development and manufacturing organization (CDMO) Tanvex BioPharma has named Stephen Lam its new chief executive (CEO). 5 September 2024
Novocure (Nasdaq: NVCR) has announced that chief executive Asaf Danziger will retire at the end of 2024, with current chief financial officer Ashley Cordova set to succeed him as CEO. 4 September 2024